Cargando…

223. Predicting Mortality Among Immunocompromised Patients Who Present With Bloodstream Infection

BACKGROUND: The revised definition of sepsis (Sepsis-3) uses Sequential Organ Failure Assessment (SOFA) and quick SOFA (qSOFA) to identify patients with sepsis instead of systemic inflammatory response syndrome (SIRS) criteria. Subsequent studies revealed contradictory results pertaining to qSOFA, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Henig, Oryan, Rao, Krishna, KB Putler, Rosemary, Patel, Twisha S, Albin, Owen, Kaye, Keith S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810590/
http://dx.doi.org/10.1093/ofid/ofz360.298
_version_ 1783462291981729792
author Henig, Oryan
Rao, Krishna
KB Putler, Rosemary
Patel, Twisha S
Albin, Owen
Kaye, Keith S
author_facet Henig, Oryan
Rao, Krishna
KB Putler, Rosemary
Patel, Twisha S
Albin, Owen
Kaye, Keith S
author_sort Henig, Oryan
collection PubMed
description BACKGROUND: The revised definition of sepsis (Sepsis-3) uses Sequential Organ Failure Assessment (SOFA) and quick SOFA (qSOFA) to identify patients with sepsis instead of systemic inflammatory response syndrome (SIRS) criteria. Subsequent studies revealed contradictory results pertaining to qSOFA, and limited data are available for immunocompromised patients. The objectives of this study were to (1) evaluate the performance of Sepsis -3 in a cohort of immunocompromised patients with microbiologically-proven sepsis, defined as having received antibiotics and having bloodstream infection (BSI); and (2) to compare its performance in the BSI cohort to its performance in immunocompromised patients who received antibiotics but did not have BSI (Non-BSI cohort). METHODS: Adult patients with hematologic malignancy or solid transplant recipients admitted to Michigan Medicine between 2012–2017 with suspected infection were included based on criteria used in the Sepsis-3 study: having both a body fluid culture and having received intravenous antibiotics. SOFA, qSOFA and SIRS components within 1 day of the index date (culture date or antibiotic date, whichever came first) were extracted from the medical record. For each group, a baseline risk model for mortality was created including age, gender, race, and Charlson comorbidity index. Each score (SOFA ≥ 2, qSOFA ≥ 2, SIRS ≥ 2) was added to the baseline risk model as a dichotomous variable and AUROC values were calculated. RESULTS: 2822 patients with a mean age of 56.8±15.6 were included. 349 (12.4%) had BSI. The most common immune compromising conditions were solid-organ transplantation (47%), lymphoma (21.3%) and acute leukemia (17%). 14% of patients in the BSI cohort died during hospitalization compared with 6.6% in the non-BSI cohort (P < 0.001). For the BSI cohort, when SOFA ≥ 2, qSOFA ≥ 2, SIRS ≥ 2 scores were added to the model, the AUROC values were less than those for the non-BSI cohort (table). The addition of SOFA ≥6 to the baseline risk model produced the highest AUROC values in both the BSI and non-BSI cohorts (figure). CONCLUSION: Among immunocompromised patients, an SOFA score ≥6 was the strongest predictor of mortality. Surprisingly, sepsis scores performed better in the non-BSI cohort than in the BSI cohort. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810590
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68105902019-10-28 223. Predicting Mortality Among Immunocompromised Patients Who Present With Bloodstream Infection Henig, Oryan Rao, Krishna KB Putler, Rosemary Patel, Twisha S Albin, Owen Kaye, Keith S Open Forum Infect Dis Abstracts BACKGROUND: The revised definition of sepsis (Sepsis-3) uses Sequential Organ Failure Assessment (SOFA) and quick SOFA (qSOFA) to identify patients with sepsis instead of systemic inflammatory response syndrome (SIRS) criteria. Subsequent studies revealed contradictory results pertaining to qSOFA, and limited data are available for immunocompromised patients. The objectives of this study were to (1) evaluate the performance of Sepsis -3 in a cohort of immunocompromised patients with microbiologically-proven sepsis, defined as having received antibiotics and having bloodstream infection (BSI); and (2) to compare its performance in the BSI cohort to its performance in immunocompromised patients who received antibiotics but did not have BSI (Non-BSI cohort). METHODS: Adult patients with hematologic malignancy or solid transplant recipients admitted to Michigan Medicine between 2012–2017 with suspected infection were included based on criteria used in the Sepsis-3 study: having both a body fluid culture and having received intravenous antibiotics. SOFA, qSOFA and SIRS components within 1 day of the index date (culture date or antibiotic date, whichever came first) were extracted from the medical record. For each group, a baseline risk model for mortality was created including age, gender, race, and Charlson comorbidity index. Each score (SOFA ≥ 2, qSOFA ≥ 2, SIRS ≥ 2) was added to the baseline risk model as a dichotomous variable and AUROC values were calculated. RESULTS: 2822 patients with a mean age of 56.8±15.6 were included. 349 (12.4%) had BSI. The most common immune compromising conditions were solid-organ transplantation (47%), lymphoma (21.3%) and acute leukemia (17%). 14% of patients in the BSI cohort died during hospitalization compared with 6.6% in the non-BSI cohort (P < 0.001). For the BSI cohort, when SOFA ≥ 2, qSOFA ≥ 2, SIRS ≥ 2 scores were added to the model, the AUROC values were less than those for the non-BSI cohort (table). The addition of SOFA ≥6 to the baseline risk model produced the highest AUROC values in both the BSI and non-BSI cohorts (figure). CONCLUSION: Among immunocompromised patients, an SOFA score ≥6 was the strongest predictor of mortality. Surprisingly, sepsis scores performed better in the non-BSI cohort than in the BSI cohort. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810590/ http://dx.doi.org/10.1093/ofid/ofz360.298 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Henig, Oryan
Rao, Krishna
KB Putler, Rosemary
Patel, Twisha S
Albin, Owen
Kaye, Keith S
223. Predicting Mortality Among Immunocompromised Patients Who Present With Bloodstream Infection
title 223. Predicting Mortality Among Immunocompromised Patients Who Present With Bloodstream Infection
title_full 223. Predicting Mortality Among Immunocompromised Patients Who Present With Bloodstream Infection
title_fullStr 223. Predicting Mortality Among Immunocompromised Patients Who Present With Bloodstream Infection
title_full_unstemmed 223. Predicting Mortality Among Immunocompromised Patients Who Present With Bloodstream Infection
title_short 223. Predicting Mortality Among Immunocompromised Patients Who Present With Bloodstream Infection
title_sort 223. predicting mortality among immunocompromised patients who present with bloodstream infection
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810590/
http://dx.doi.org/10.1093/ofid/ofz360.298
work_keys_str_mv AT henigoryan 223predictingmortalityamongimmunocompromisedpatientswhopresentwithbloodstreaminfection
AT raokrishna 223predictingmortalityamongimmunocompromisedpatientswhopresentwithbloodstreaminfection
AT kbputlerrosemary 223predictingmortalityamongimmunocompromisedpatientswhopresentwithbloodstreaminfection
AT pateltwishas 223predictingmortalityamongimmunocompromisedpatientswhopresentwithbloodstreaminfection
AT albinowen 223predictingmortalityamongimmunocompromisedpatientswhopresentwithbloodstreaminfection
AT kayekeiths 223predictingmortalityamongimmunocompromisedpatientswhopresentwithbloodstreaminfection